MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
34.42
+1.14
+3.43%
Opening 12:27 09/30 EDT
OPEN
33.20
PREV CLOSE
33.28
HIGH
35.12
LOW
33.20
VOLUME
300.38K
TURNOVER
5.23M
52 WEEK HIGH
84.83
52 WEEK LOW
26.81
MARKET CAP
3.64B
P/E (TTM)
-23.2662
1D
5D
1M
3M
1Y
5Y
Akero adds over 100% rallying peers after NASH success
Akero Therapeutics (NASDAQ:AKRO), a biotech focused on n...
Seekingalpha · 09/13 16:08
Morgan Stanley Initiates Coverage On Arrowhead Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $41
Morgan Stanley analyst Andrew Galler initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Equal-Weight rating and announces Price Target of $41.
Benzinga · 09/09 11:48
Morgan Stanley Starts Arrowhead Pharmaceuticals at Equalweight Rating With $41 Price Target
Morgan Stanley Starts Arrowhead Pharmaceuticals at Equalweight Rating With $41 Price Target
MT Newswires · 09/09 09:59
Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 982% gain
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders have seen the share price descend 19% over the month. But...
Simply Wall St. · 09/07 10:46
Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Arrowhead Pharmaceuticals (NASDAQ:ARWR) <a href="...
Seekingalpha · 08/17 12:48
BRIEF-Arrowhead files for regulatory clearance to initiate Phase 1/2A study of ARO-MMP7 for idiopathic pulmonary fibrosis
BRIEF-Arrowhead files for regulatory clearance to initiate Phase 1/2A study of ARO-MMP7 for idiopathic pulmonary fibrosis
Reuters · 08/17 11:37
Arrowhead Files For Regulatory Clearance To Initiate Phase 1/2a Study Of ARO-MMP7 For Idiopathic Pulmonary Fibrosis
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi)
Benzinga · 08/17 11:35
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
PASADENA, Calif., August 17, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) thera...
Business Wire · 08/17 11:30
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.